Arbutus Biopharma Corp (ABUS) Investment Research Dashboard
About Arbutus Biopharma Corp (ABUS) stock analysis
Get live ABUS stock price $4.45, comprehensive Arbutus Biopharma Corp stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ABUS stock data and investment insights.
Loading chart data...
Arbutus Biopharma Corp (ABUS) Overview
Arbutus Biopharma Corp (ABUS) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, ABUS trades at $4.45 with a market capitalization of 879.04M . Over the past 52 weeks, ABUS has traded between $3.25 and $5.38 , with the current price positioned at approximately 56% of this range . The stock currently trades a...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 879.04M
- Current price: $4.45
- 52-week range: $3.25 - $5.38
- P/E ratio: 5.36
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-...
Company Information
- CEO
- Lindsay Androski
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
Contact Information
- Website
- http://www.arbutusbio.com
- Address
- 701 Veterans Circle
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Listed on major US exchange (NASDAQ) providing liquidity and transparency
✓ Valuation metrics suggest potential value opportunity (P/E: 5.4)
✓ Lower volatility stock (Beta: 0.62) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Arbutus Biopharma Corp shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Arbutus Biopharma Corp
- ⚠Investors should consider how Arbutus Biopharma Corp fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
879.04M
P/E Ratio (TTM)
5.36
Beta
0.62
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare ABUS with peer companies:
- Price
- $28.15+3.63% (1D)
- Market cap
- 1.54B
- Price
- $12.66+3.36% (1D)
- Market cap
- 1.06B
- Price
- $28.21+3.41% (1D)
- Market cap
- 1.93B
- Price
- $10.63+2.02% (1D)
- Market cap
- 943.67M
- Price
- $40.59+2.24% (1D)
- Market cap
- 2.05B
- Price
- $1.57+4.67% (1D)
- Market cap
- 232.62M
- Price
- $33.79+2.08% (1D)
- Market cap
- 1.52B
- Price
- $5.86-1.85% (1D)
- Market cap
- 581.92M
- Price
- $5.62+1.63% (1D)
- Market cap
- 1.15B
- Price
- $27.08+1.37% (1D)
- Market cap
- 3.37B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
81/100 ⭐⭐⭐⭐⭐
- Overall
- +0.3%
- NYSE
- -0.1%
- NASDAQ
- +0.8%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.1% | +1.3% | +2.0% | 19.3 | 82/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.3% | +2.8% | +1.6% | 23.6 | 81/100⭐⭐⭐⭐⭐ |
| Communication Services | +0.8% | -2.0% | +2.3% | 22.2 | 70/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | +1.1% | +1.3% | +0.1% | 29.0 | 66/100⭐⭐⭐⭐ |
| Energy | +0.9% | +0.7% | -1.3% | 19.7 | 64/100⭐⭐⭐⭐ |
| Real Estate | -0.4% | +2.3% | -1.5% | 29.6 | 54/100⭐⭐⭐ |
| Basic Materials | -0.4% | +0.7% | -1.5% | 25.0 | 46/100⭐⭐⭐ |
| Utilities | -1.0% | +2.2% | -2.2% | 25.6 | 44/100⭐⭐⭐ |
| Consumer Cyclical | +0.5% | -1.4% | -3.8% | 42.9 | 18/100⭐ |
| Industrials | -0.8% | -0.4% | -9.2% | 30.6 | 13/100⭐ |
| Technology | -1.9% | -1.1% | -5.6% | 42.0 | 12/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-27.